Assessing the Impact of Pegylated-Interferon/Ribavirin Therapy Duration Versus Viral Response on Health-Related Quality of Life (Qol) Outcomes in Chronic Hepatitis C Virus (Hcv) Patients, Using Multivariate Mixed-Effects Modeling
Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.1411
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Elsevier BV